In a speech to senior pharmaceutical industry executives earlier this year, FDA commissioner Mark D. McClellan MD, PhD, openly criticised Europe for not paying its fair share of drug development costs. European governments' prescription drug pricing controls, he suggested, are forcing Americans to shoulder more than their fair share of the burden, resulting in much higher prices in the US than anywhere else in the world.
European companies—forced to focus on the US market to generate the bulk of their profits—agree: low European prices put them at a distinct financial disadvantage.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?